PubMed:32178765 / 1267-1526 JSONTXT

Annnotations TAB JSON ListView MergeView

    Inflammaging

    {"project":"Inflammaging","denotations":[{"id":"T9","span":{"begin":0,"end":259},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":259},"obj":"Sentence"}],"text":"Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo."}

    yaoziqian_800_3

    {"project":"yaoziqian_800_3","denotations":[{"id":"T10","span":{"begin":251,"end":258},"obj":"CI"},{"id":"T8","span":{"begin":153,"end":163},"obj":"CI"},{"id":"T9","span":{"begin":186,"end":196},"obj":"CI"}],"text":"Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo."}

    Zierdiyeerkenaili_800_3

    {"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T10","span":{"begin":153,"end":163},"obj":"CI"},{"id":"T11","span":{"begin":186,"end":196},"obj":"CI"},{"id":"T18","span":{"begin":251,"end":258},"obj":"CI"}],"text":"Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo."}